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E-mail address: ywfung2002@gmail.com (Y.-W.W.Four-and-a-half LIM domain protein 1B (FHL1B) is an alternatively-spliced isoform of FHL1. In this
study, FHL1B was demonstrated to interact with the b catalytic subunit (Cb) of a type 2A protein
phosphatase (PP2A) by yeast two-hybrid screening. Domain studies using a small-scale yeast two-
hybrid interaction assay revealed the mediation of protein-protein interaction by FHL1B’s C-termi-
nus. Interaction between FHL1B and PP2A was further veriﬁed by co-immunoprecipitation. FHL1B
was also shown to shuttle between nucleus and cytoplasm at different phases of the cell cycle. These
data suggest that the FHL1B/PP2ACb interaction may illustrate a novel cell-cycle regulatory pathway.
Structured summary:
MINT-8044739: FHL1B (uniprotkb:Q13642-2) physically interacts (MI:0915) with PP2Acbeta (uni-
protkb:P62714) by two hybrid (MI:0018)
MINT-8044769, MINT-8044778: FHL1B (uniprotkb:Q13642-2) physically interacts (MI:0915) with PP2Acb-
eta (uniprotkb:P62714) by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Four-and-a-half LIM domain proteins (FHL) have been widely
studied in recent years. Each LIM domain contains a double zinc
ﬁnger motif with the consensus sequence of C2HC and C4 [1]
The FHL family includes FHL1 (or SLIM1), FHL2, FHL3, FHL4, and
ACT in humans [2–4]. Expression patterns of the FHL family
members suggest important functional roles in skeletal muscle
and cardiovascular system [5]. FHL1 is expressed in a relatively
high level in human skeletal muscle [5,6]. The expression of
FHL1 is down-regulated in human hypertrophic cardiomyopathy
and failing hearts [7]. Two novel alternatively spliced isoforms
of the human FHL1 have been identiﬁed, designated FHL1B [6]
(or KyoT3 [8,9]) and FHL1C [10,11]. The protein sequence of
FHL1B also contains three nuclear localization signal (NLS) motifs,
a nuclear exportation sequence (NES) and a J-recombination sig-
nal protein (RBP-J) binding domain at the C-terminus [6]. Being
predominantly located in cell nuclei, FHL1B is expected to be
translocated from the nucleus to the cytoplasm with its available
NLS and NES [6].chemical Societies. Published by E
Fung).Using the yeast two-hybrid screening method, we isolated a b
catalytic subunit of protein phosphatase 2A (PP2ACb), which could
interact with FHL1B. PP2A is a member of the serine/threonine
phosphatase family, which is involved in many metabolic or regu-
latory pathways including transcription, translation, cell cycle reg-
ulation, cellular differentiation, cell regulation of speciﬁc signal
transduction cascades and oncogenic transformation [12–14]. Its
catalytic activity, substrate speciﬁcity and subcellular localization
are modulated by its regulatory subunits [15]. The trimeric holoen-
zyme complex of PP2A consists of an enzymatically active 36-kDa
catalytic C subunit (a, b) and a 65-kDa structural A/PR65 subunit
(a, b), which act as scaffold assembly subunits, and a regulatory
B subunit [15]. Both Ca and Cb subunits are ubiquitously expressed
in various tissues [16]. Interestingly, high expression levels of Ca
and Cb subunits are found in the brain and heart [17,18], as has
been observed for FHL1B. Some regulatory B subunits of PP2A con-
tain putative NLS that may be responsible for the nuclear localiza-
tion of PP2A [19]. The B subunits can also direct PP2A to various
intracellular locations for mediating its functions, and are respon-
sible for substrate speciﬁcity [15]. All types of A and C subunits
could be expressed in cells, while only some classes of B isotypes
are found to be expressed in speciﬁc tissues or different develop-
mental stages [15].lsevier B.V. All rights reserved.
4512 C.-H. Wong et al. / FEBS Letters 584 (2010) 4511–4516In light of the putative importance of FHL1B and PP2A in cellu-
lar regulation, we report here the interaction between FHL1B and
the b catalytic subunit of PP2A. Our study indicates that one of
the roles of FHL1B is to act as a speciﬁc regulator of PP2A in human
muscles and brain.2. Materials and methods
2.1. Cell culture
Human rhabdomyosarcoma cells (RD, ATCC number: CCL-136)
and Mus muculus myoblast cell line
C2C12 (ATCC number: CRL-1772) were maintained in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen, USA) sup-
plemented with 10% fetal bovine serum (Invitrogen) at 37 C, and
kept in 95% air and 5% CO2.
2.2. Yeast two-hybrid library screening
Saccharomyces cerevisiae strains Y187 (HIS3 and lacZ reporters)
and Y190 (lacZ reporter), two-hybrid GAL4 DNA-binding domain
(DNA-BD) fusion vector, pAS2-1, and GAL4 activation domain
(AD) fusion vectors, pACT-1, obtained from the MATCHMAKER
Two-Hybrid System (BD Biosciences) were used in the yeast two-
hybrid screening. FHL1B cDNA was subcloned into pAS2-1 using
a pair of primers ﬂanking the open reading frame (ORF) of FHL1B
(Supplementary Table 1). Pre-transformed brain cDNA library
(BD Biosciences) constructed in pACT-1 was used in the screening
with the ‘‘bait” protein FHL1B. Before the screening procedures
were performed, the pAS2-1/FHL1B hybrid construct was veriﬁed
for its in vivo transcriptional activation using the Yeast TransAct
Assay (BD Biosciences). The pAS2-1/FHL1B was introduced into S.
cerevisiae strain Y187 using small-scale yeast transformation by
the lithium acetate (LiAc) method. Trp+ transformants were tested
for expression of lacZ reporter gene by the blue/white screening of
the colony lift b-galactosidase ﬁlter assay. Control transformations
were also performed in parallel. In the actual yeast two-hybrid
screening, pAS2-1/FHL1B and pACT-1/brain cDNA were co-trans-
formed into the yeast reporter strain Y190, using the LiAc method.
All procedures were carried out in accordance with the manufac-
turer’s instructions (BD Biosciences). Putatively positive library
plasmids were rescued from the transformants. Interaction was
further conﬁrmed by co-transforming the library plasmid of inter-
est and pAS2-1/FHL1B into Y187.
2.3. Deletion study: interacting domains of FHL1B with PP2ACb
pAS2-1/FHL1B (1-246), pAS2-1/FHL1B (1-230), pAS2-1/FHL1B
(231-323) and pAS2-1/FHL1B (247-323) were constructed using
a combination of either forward or reverse primers (Supplemen-
tary Table 1) for amplifying FHL1B (ORF) and FHL1B deletion mu-
tants. Interactions of different deletion mutants of FHL1B with
PP2ACb were determined by a series of co-transformation of dif-
ferent combinations of constructs into yeast strain Y190 as de-
scribed above.
2.4. Antibody production
For the production of anti-FHL1B antibody, speciﬁc antisera
were raised by immunizing a rabbit with an acetylated FHL1B syn-
thetic peptide, residues 231–246 (Ac-KRTVSRVSHPVSKARK) (Invit-
rogen). An injection of the conjugated peptide was carried out
every month for a total of ﬁve times and blood was drawn after
each injection except for the ﬁrst injection. Antiserum from each
blood sample was obtained and stored at 20 C. Polyclonal IgGantibodies were puriﬁed using HiTrap Protein G afﬁnity column
(GE Healthcare).
2.5. Co-immunoprecipitation (Co-IP)
Human RD cells (2  106) were seeded on 100 mm culture
dish and washed twice with ice cold PBS. Cell lysis was carried
out on ice with 500 ll co-IP buffer for 15 min. Cell lysate was
pre-cleared with protein G agarose (Roche Applied Science) for
1 h with shaking at 4 C. The protein G agarose was removed by
centrifugation, and antibody against FHL1B or PP2A (Millipore,
USA) was added to the supernatant for 1.5 h incubation with shak-
ing at 4 C. Afterwards, 30 ll protein G agarose was added and
incubated at 4 C for 2 h with shaking. The immuno-complex was
centrifuged, washed with washing buffer and incubated in SDS
loading buffer with DTT for 10 min at 100 C. SDS–PAGE gel elec-
trophoresis (15%) was carried out and Western blot using anti-
FHL1B or anti-PP2AC antibodies to probe for the respective protein
partners in the immuno-complex.
2.6. Cloning of cDNA of interest into pEGFP-C1 vector
PCR was performed in the presence of each of the PP2ACb for-
ward and reverse primers (Supplementary Table 1). PCR amplicon
of expected size was cloned into pEGFP-C1 vector. The construc-
tion of GFP-FHL1B into the pEGFP-C1 vector has been previously
described [2].
2.7. Subcellular localization study
GFP-FHL1B and GFP-PP2ACb were transfected into C2C12 and
RD cells for 24 h using Lipofectamine Plus reagent (Invitrogen), in
accordance with the manufacturer’s protocol. Cells were then ﬁxed
in 3.7% paraformaldehyde for 10 min at room temperature, washed
in PBS and stained with 300 ng/ml DAPI solution for nucleus visu-
alization. Epi-ﬂuorescence microscopy was used, and images were
captured by a CCD camera (Photometrics, USA) and colored artiﬁ-
cially using the IPLab™ software (BD Biosciences). GFP signals
were observed under the GFP ﬁlter set, with DAPI signals under
the DAPI ﬁlter set.
2.8. Cell cycle synchronization and arrest
Cells were seeded in a 100 mm culture dish for protein lysate
collection or on a sterilized cover-glass for microscopic examina-
tion. For cell cycle arrest, 1 lg/ml Aphidicolin (Sigma) or 400 ng/
ml of Nocodazole (Sigma) was included in the complete DMEM
(10% FBS/1% PS) for G1 blockage or early mitotic arrest, respec-
tively. Cells were incubated with the drugs for 24 h. Serum starva-
tion (DMEM/1% FBS) for 72 h was used to drive the cells into G0
phase.
2.9. Flow cytometry measurement
After trypsinization and two washes by PBS, cells were ﬁxed
in ice cold 70% ethanol at 20 C overnight, and then incubated
in a propidium iodide (PI) mixture (50 lg/ml PI, 0.1 mg/ml
RNase A, 0.05% Triton X-100 in PBS) at 37 C for 30 min. Fixed
cells were analyzed by the FACsort ﬂow cytometer (BD Biosci-
ences). Data acquisition and analyses were performed using the
CellQuest software (BD Biosciences). 10 000 events were col-
lected for each analysis. PI signals were detected by the FL2-A
channel. The percentage of cell population was estimated by
WinMDI software version 2.8 (free download at, http://facs.-
scripps.edu/software.html).
Fig. 1. Small scale yeast two-hybrid assay to pinpoint interacting domains of FHL1B. Interaction was veriﬁed by the ability of co-transformants to grow on SD agar plates
lacking Leu/Trp/His, and to produce blue colonies (b-galactosidase activity) in ﬁlter lift assays. After developing for 10 h, the co-transformants were classiﬁed as positives
(dark blue [+++], blue [++], pale blue [+]) or negatives (white []). N1N2 represents the ﬁrst and second NLS, while N2N3 represents the second and the third NLS.
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C2C12 cells were transfected with GFP or GFP-FHL1B vector and
treated with appropriate drugs for different cell cycle arrests.
Twenty-four hours post-transfection, cells were harvested and pro-
tein extraction from four subcellular fractions was achieved using
the ProteoExtract Subcellular Proteome Extraction Kit (EMD Chem-
icals Inc., USA). Protein amount of each fraction was determined by
Bradford reagent (BioRad). Ten micrograms of protein from each
fraction was separated on a 12% SDS–PAGE gel and Western blot
was performed using anti-GFP antibody (BD Biosciences) for the
detection of GFP and also GFP-FHL1B in different phases of cell cy-
cle and in different cellular compartments.
3. Results
3.1. Identifying PP2ACb as an interacting partner of FHL1B
Approximately 4 million cDNA clones were screened in the
yeast two-hybrid library screening. After a series of screenings to
eliminate false positive clones, the putative positive clones were
isolated from yeast. The insert of one of the positive clones was
identiﬁed as PP2ACb, putative interacting partners of FHL1B. The
speciﬁcity of the interaction between FHL1B and PP2ACb was fur-
ther veriﬁed by re-transforming the pACT2/PP2ACb plasmid with
the pAS2/FHL1B, or with controls (pACT2/PP2ACb alone, pACT2/
PP2ACb with pAS2/no insert, or pACT2/PP2ACb with pAS2/lamin C
as unrelated control), into the yeast reporter strains, HF7c and
SFY526. Only the transformation with pACT2/PP2ACb and pAS2/
FHL1B produced transformants that could grow on SD agar plates
lacking Leu/Trp/His and could produce blue colonies with colony
lift b-galactosidase ﬁlter assay.Fig. 2. Veriﬁcation of PP2ACb/FHL1B interaction by co-immunoprecipitation. Cell
lysate was prepared from RD cells. Using PP2A or FHL1B antibody, protein
complexes were immunoprecipitated respectively with Protein G agarose and then
separated on a 15% SDS–PAGE gel, followed byWestern blotting. (Right panel) A 34-
kDa band can be observed when using anti-FHL1B antibody in Western blot after
pull-down by the anti-PP2A antibody. (Left panel) A 36-kDa band can be seen when
using anti-PP2A antibody in Western blot after pull-down by the anti-FHL1B
antibody. In the control lane of each panel, only protein G agarose was used in the
pull-down; no band would be expected in Western blotting.3.2. FHL1B deletion mutants
Using yeast two-hybrid, the interacting domain on FHL1B was
determined by studying the interaction of PP2ACb with different
N-terminal or C-terminal truncated mutants of FHL1B. Each of
the different FHL1B mutants (FHL1B [a.a. 1–230], FHL1B [a.a. 1–
246], FHL1B [a.a. 231–323], full-length FHL1B, and FHL1C, fused
with GAL-BD, were co-expressed with full-length PP2ACb fused
with GAL-AD in Y187 reporter strain. The interaction of PP2ACb
and each FHL1B variation was tested by the ability of co-transfor-
mants to generate blue colonies in the b-galactosidase ﬁlter assay.
The results showed that the protein interaction was greatly re-
duced when either FHL1B [a.a. 1–230 or 1–246] mutant containing
three and a half LIM domains or the full-length FHL1C was co-ex-
pressed with PP2ACb Fig. 1). However, the interaction between
PP2ACb and FHL1B [a.a. 231–323] was comparable to that of full-
length FHL1B (Fig. 1), suggesting that NLS and NES followed by
an unknown fragment of 31 a.a. sequence in FHL1B could be
responsible for binding with PP2ACb. A negative control was
accomplished by co-transforming different FHL1B mutants with
pGAD424 vector without insert.
3.3. Co-IP assay: verifying FHL1B/PP2ACb interaction
To further conﬁrm the physical interaction, co-IP was per-
formed to determine whether FHL1B would form a binding com-
plex with PP2ACb. Fig. 2 illustrates that both FHL1B and PP2ACb
could be co-immunoprecipitated by either anti-FHL1B or anti-
PP2A antibodies. These data demonstrate that the speciﬁc interac-
tion of FHL1B and PP2ACb can be demonstrated in vivo and that the
interaction is direct. (Fig. S1 shows the approximate size of PP2ACb
and FHL1B as obtained by in vitro translation with rabbit reticulo-
cyte lysate.)
3.4. Subcellular localization of FHL1B and PP2ACb during cell cycle
progression
To study the subcellular localization of the FHL1B and PP2ACb,
the full-length cDNAs of these two genes were cloned into the pEG-
FP-C1 expression vector. After transfection into C2C12 and RD cells
for 24 h, cells were ﬁxed and the location of the GFP fusion protein
was examined. GFP-FHL1B fusion protein was predominantly
localized in the nuclei of both cell types (Fig. 3A), whereas GFP-
PP2ACb fusion protein was present in all cellular compartments
(Fig. 3B). To study the shuttling of FHL1B during cell cycle progres-
sion, GFP-FHL1B was transfected into C2C12 cells arrested in G0,
G1, or early G2/M phase by serum starvation or appropriate drugs.
In Fig. 4, FHL1B is seen to be shuttling out of nuclei in G2 arrested
cells. Fig. S2 shows co-visualization of PP2ACb and FHL1B in C2C12
cell at interphase. Subcellular proteome fractionation was also
Fig. 3. Subcellular localization of GFP-FHL1B and GFP-PP2ACb fusion proteins in cells. (A) GFP-FHL1B is predominantly localized in the nuclei; (B) GFP-PP2ACb is localized in
both the nucleus and the cytoplasm. Bar = 50 lm.
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skeletal fractions. The Western blot results indicate a reduced level
of GFP-FHL1B in the nuclear fraction of cells arrested in G2 phase
(Fig. 5).
4. Discussion
FHL1B and FHL1 are protein isoforms generated from the same
gene by alternatively splicing. FHL1 mRNA can be detected as early
as embryonic day (E) 8.5, with high expression in the outﬂow tract
[5]. The expression of FHL1 (also called SLIM1 or KyoT in mice) is
down-regulated in dilated cardiomyopathic hearts [20]. Levels of
FHL1 mRNA are down-regulated in disuse atrophy and up-regu-
lated in stretch induced hypertrophy [21]. Therefore, FHL1B may
play a crucial role in the human heart or skeletal muscles. Tofurther elucidate the roles of FHL1B, we performed the yeast
two-hybrid screening to identify PP2ACb as a binding partner of
FHL1B. The interaction between FHL1B and PP2ACb was further
conﬁrmed by co-IP and deletion mutants of FHL1B suggested bind-
ing with PP2ACb as mediated by its non-LIM domains, in contrast to
the adapter role of the LIM domains in bringing proteins together.
Ubiquitously expressed PP2A makes up 1% of total cellular
proteins and along with protein phosphatase 1 (PP1) accounts for
over 90% of all serine/threonine phosphatase activity in the cell
[15]. Deletion of the catalytic subunit is lethal in yeast and mice,
suggesting the essential function of PP2AC [22,23]. The expression
of PP2AC is expected to be tightly controlled to ensure relatively
constant levels of PP2A during different phases of the cell cycle
in mammalian cells [24]. Regulatory mechanisms of PP2A probably
involves its dynamic association and dissociation with different
Fig. 4. Subcellular localization of GFP-FHL1B in different cell cycle phases. GFP control panel: expression of GFP only in C2C12 cells. Subcellular localization of GFP did not
change in G0, G1 arrest and G2/M arrest when compared with normal control. GFP-FHL1B panel: GFP-FHL1B expression patterns in different phases of the cell cycle. In the
normal control, G0, and G1 arrested samples, GFP-FHL1B was mainly located in the nucleus, with only trace amounts in the cytoplasm. But in the G2/M arrest sample, GFP-
FHL1B was excluded from the nucleus in a majority of cells that remained in interphase, indicating the ability of FHL1B to shuttle between cytoplasm and nucleus during G2
phase. Bar = 50 lm. FACS panel shows the population of cells in different cell cycle phases.
C.-H. Wong et al. / FEBS Letters 584 (2010) 4511–4516 4515regulatory proteins, e.g., the cell cycle regulation of PP2A is modu-
lated by the association and dissociation of different regulatory B


























































Fig. 5. Western blot analysis of proteins from different cellular compartments during diff
cytoskeletal fractions. The same amount of protein was analyzed, using anti-GFP antibo
nuclear fraction, consistent with the results of microscopic examination.In this study, we propose a role for FHL1B in targeting the
appropriate substrates to PP2A during cell cycle progression.
















































erent cell cycle phases. Proteins were divided into cytosolic, membrane, nuclear, and
dy. The amount of GFP-FHL1B was signiﬁcantly reduced in the G2 phase arrested
4516 C.-H. Wong et al. / FEBS Letters 584 (2010) 4511–4516acting as a protein interface to interact with proteins possessing
LIM domains and other protein domains [1]. The LIM domains of
FHL1B may bind to some speciﬁc substrates, resembling the func-
tion of B regulatory subunit in modulating substrate speciﬁcity of
PP2A phosphorylation reactions [15]. Another possible function
of FHL1B is to bring PP2A to speciﬁc sites or cellular compartments
for regulatory functions, similar to the focal adhesion localization
of FHL2 and FHL3 [4]. By the same principle, PP2ACbmay be accom-
panied by other proteins that are involved in the regulatory func-
tions and interact with FHL1B. The B0 family (PR61), one of the
regulatory subunit families of PP2AC, has an NLS domain that is
proposed to be related to the nuclear localization of PP2A [4,19].
FHL1B, which interacts with PP2ACb, also possesses a NLS domain
that may exert function similar to the B0 family (PR61), by modu-
lating nuclear localization or shuttling between cytoplasm and nu-
cleus in different cell cycle phases in order to exert the regulatory
effect of PP2A at the appropriate time and correct place.
FHL1B is highly expressed in the nucleus of myoblast and is
exclusively cytosolic in myotubes [25]. In the subcellular localiza-
tion study of myoblasts during various cell cycle phases, we have
shown that the amount of FHL1B is reduced in the early mitotic ar-
rested nucleus by both ﬂuorescence microscopy and Western blot
analysis of subcellular proteome fractions. These results suggest
that FHL1B is not only excluded from the nucleus in fully differen-
tiated muscle myotubes, but also shuttles in between the cyto-
plasm and the nucleus during the progression of cell cycle. The
presence of NLS and NES in FHL1B also supports the role of FHL1B
in shuttling between cytoplasm and nucleus. It is possible that
FHL1B also binds to a speciﬁc nuclear-export receptor in the nu-
cleus through the leucine-rich NES sequences at the C-terminus.
In conclusion, we have demonstrated the interaction of FHL1B
and PP2ACb in vitro and in vivo. The interaction of FHL1B and
PP2ACb may indicate a novel cell cycle regulatory pathway. FHL1B
could be responsible for recruiting other PP2A-related proteins to
mediate subsequent regulatory processes involved in cell cycle.
The next step is to identify the binding domain on PP2A by FHL1B,
to better understand the signiﬁcance of PP2A and FHL1B interac-
tion in cell cycle regulation.
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